Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia.
Silvia Lo Monaco(University of Bologna), Giovanni Martinelli(University of Bologna), Valentina Robustelli(University of Bologna), Anna Ferrari(University of Bologna), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Maria Chiara Fontana(Istituto Oncologico Romagnolo), Maria Chiara Abbenante(University of Bologna), Emanuela Ottaviani(University of Bologna), Giovanni Marconi(University of Bologna), Jacopo Nanni(Istituto di Ematologia di Bologna), Eugenia Franchini(University of Bologna), Sarah Parisi(University of Bologna), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Nicoletta Testoni(Thrombolysis in Myocardial Infarction Study Group), Antonella Padella(University of Bologna), Carmen Baldazzi(University of Bologna), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Luca Bertamini(University of Verona), Eugenio Fonzi(University of Bologna)
Cited by 0
Related Papers
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
|The Lancet Oncology|2019|486